Gelonghui December 4th | Henan Lingrui Pharmaceutical (600285.SH) announced that the company plans to use its own funds to acquire 100% equity of Yingu Pharmaceutical Co., Ltd. (referred to as "Yingu Pharmaceutical", the "target company"). The company signed a "Acquisition Intention Letter of Intent" with Yingu Holdings Group Co., Ltd. and Mr. Wang Wenjun, reaching a preliminary cooperation intention on the equity acquisition. The company plans to use its own funds to purchase 100% equity of the target company. Based on the preliminary evaluation of the business, finance, and team of the target company, its comprehensive valuation is tentatively set at no more than RMB 782.12 million (final valuation will be based on the valuation stated in the evaluation report and audit report issued by a third-party professional institution, determined by negotiation among the company and the trading parties). Other shareholders of Yingu Pharmaceutical have authorized Yingu Group to negotiate the equity transfer on their behalf.
Yingu Pharmaceutical independently completed the research and development and market launch of the first highly selective anticholinergic receptor antagonist Class 1 new drug in China, namely Benzilylcholine Bromide Nasal Spray (trade name: Bilitin), and also owns domestically produced generic drugs Salmon Calcitonin Injection (trade name: Gutaining), Salmon Calcitonin Nasal Spray (trade name: Jinerli); as well as Inhaled Ammonium Bromide Solution (trade name: Lixichang).